Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?

Fuente: Zenodo
Salvato in:
Dettagli Bibliografici
Autore principale: Estebanez M, Stella-Ascariz N, Ruiz-Carrascoso G, Zamora FX, García-Bujalance S, Bernardino JI, Pérez-Valero I, Martin-Quirós A, Mingorance J, Arribas JR
Natura: Recurso digital
Pubblicazione: Zenodo 2013
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1866901050797064192
author Estebanez M, Stella-Ascariz N, Ruiz-Carrascoso G, Zamora FX, García-Bujalance S, Bernardino JI, Pérez-Valero I, Martin-Quirós A, Mingorance J, Arribas JR
author_facet Estebanez M, Stella-Ascariz N, Ruiz-Carrascoso G, Zamora FX, García-Bujalance S, Bernardino JI, Pérez-Valero I, Martin-Quirós A, Mingorance J, Arribas JR
contents <div> <div> <h2>Abstract</h2> <div> <p>We report long-term virologic response to etravirine and tenofovir/emtricitabine in four HIV-1-infected patients who had prior standard genotypic resistance testing showing an isolated K103N mutation (three acquired, one transmitted). In three patients tested, the K103N mutation was detected in cellular HIV-1 DNA whereas remaining suppressed on etravirine plus tenofovir/emtricitabine.</p> </div> </div> </div>
format Recurso digital
id zenodo_https___doi_org_10_1097_QAD_0b013e328358fcc2
institution Zenodo
language
publishDate 2013
publisher Zenodo
record_format zenodo
spellingShingle Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?
Estebanez M, Stella-Ascariz N, Ruiz-Carrascoso G, Zamora FX, García-Bujalance S, Bernardino JI, Pérez-Valero I, Martin-Quirós A, Mingorance J, Arribas JR
<div> <div> <h2>Abstract</h2> <div> <p>We report long-term virologic response to etravirine and tenofovir/emtricitabine in four HIV-1-infected patients who had prior standard genotypic resistance testing showing an isolated K103N mutation (three acquired, one transmitted). In three patients tested, the K103N mutation was detected in cellular HIV-1 DNA whereas remaining suppressed on etravirine plus tenofovir/emtricitabine.</p> </div> </div> </div>
title Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?
url https://doi.org/10.1097/QAD.0b013e328358fcc2